[ELGX] Endologix, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 7.19 Change: 0.12 (1.63%)
Ext. hours: Change: 0 (0%)

chart ELGX

Refresh chart

Strongest Trends Summary For ELGX

ELGX is in the medium-term down -38% below S&P in 2 months and down -89% below S&P in 1 year. In the long-term down -96% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States, Europe, and rest of the world. It provides minimally-invasive endovascular repair (EVAR) products that consist of stent graft and catheter delivery system under the Powerlink, IntuiTrak, AFX, and VELA brand names. The company also offers endovascular sealing product that is based on the Nellix platform to seal the aneurysm, as well as provides blood flow to the legs through two blood lumens. In addition, it offers aortic extensions and limb extensions, which attach to the main body of its EVAR device, enabling physicians to customize it to fit the patient?s anatomy; and accessories, including guidewires, snares, and catheter introducer sheaths that facilitate the optimal delivery of its EVAR products. Endologix, Inc. sells its products through direct sales force, a network of agents, and independent distributors. The company was formerly known as Radiance Medical Sys

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4.32% Sales Growth - Q/Q-5.6% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-20.58% ROE-42.54% ROI-24.29%
Current Ratio5.04 Quick Ratio3.76 Long Term Debt/Equity0.64 Debt Ratio0.24
Gross Margin71.79% Operating Margin-22.18% Net Profit Margin-32.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.61 M Cash From Investing Activities4.2 M Cash From Operating Activities-11.73 M Gross Profit26.91 M
Net Profit-11.21 M Operating Profit-9.76 M Total Assets237.76 M Total Current Assets138.41 M
Total Current Liabilities27.45 M Total Debt71.27 M Total Liabilities122.76 M Total Revenue36.67 M
Technical Data
High 52 week6.63 Low 52 week0.52 Last close0.56 Last change2.58%
RSI23.56 Average true range0.05 Beta0.63 Volume321.74 K
Simple moving average 20 days-11.21% Simple moving average 50 days-16.28% Simple moving average 200 days-77.85%
Performance Data
Performance Week3.51% Performance Month-22.41% Performance Quart-34.12% Performance Half-77.87%
Performance Year-86.79% Performance Year-to-date-21.79% Volatility daily4.84% Volatility weekly10.82%
Volatility monthly22.16% Volatility yearly76.78% Relative Volume109.64% Average Volume852.28 K
New High New Low

News

2019-03-06 07:39:22 | The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

2019-03-05 16:01:00 | Endologix Announces Approval of Reverse Stock Split

2019-02-27 10:00:43 | What Should We Expect From Endologix, Inc.’s NASDAQ:ELGX Earnings Over The Next Few Years?

2019-02-27 00:15:38 | Edited Transcript of ELGX earnings conference call or presentation 25-Feb-19 9:30pm GMT

2019-02-25 16:01:00 | Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results

2019-02-25 14:30:00 | Endologix, Inc. to Host Earnings Call

2019-02-22 09:48:02 | All You Need to Know About Endologix ELGX Rating Upgrade to Buy

2019-02-18 10:30:03 | Endologix ELGX Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2019-02-11 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-02-07 08:30:00 | Report: Developing Opportunities within Micron Technology, Endologix, Group 1 Automotive, Dana, MACOM Technology Solutions, and Fred's — Future Expectations, Projections Moving into 2019

2019-02-06 10:41:03 | WellCare Health WCG Q4 Earnings Beat Estimates, Soar Y/Y

2019-02-06 10:39:03 | Humana's HUM Q4 Earnings Surpass Estimates, Improve Y/Y

2019-02-05 09:22:02 | Centene's CNC Earnings Top Estimates in Q4, Surge Y/Y

2019-01-29 16:01:00 | Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on February 25, 2019

2019-01-22 16:01:00 | Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

2019-01-11 08:00:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-01-10 08:00:00 | Endologix Appoints John D. Zehren as Chief Commercial Officer

2019-01-07 08:00:00 | Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance

2019-01-04 08:30:00 | Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications

2018-12-21 11:15:35 | What Kind Of Shareholder Owns Most Endologix, Inc. NASDAQ:ELGX Stock?

2018-12-20 16:01:00 | Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference

2018-12-13 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-11-15 17:00:00 | Endologix Honors Innovators of Aortic Therapy at VEITHsymposium

2018-11-12 07:50:00 | Report: Developing Opportunities within Mednax, Peabody Energy, NIC, Endologix, MobileIron, and QuinStreet — Future Expectations, Projections Moving into 2018

2018-11-08 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-11-02 00:25:20 | Edited Transcript of ELGX earnings conference call or presentation 1-Nov-18 8:30pm GMT

2018-11-01 18:30:10 | Endologix ELGX Reports Q3 Loss, Tops Revenue Estimates

2018-11-01 17:24:39 | Endologix: 3Q Earnings Snapshot

2018-11-01 16:01:00 | Endologix Reports Third Quarter 2018 Financial Results

2018-10-29 16:01:00 | Endologix, Inc. to Present at Two Investor Conferences in November

2018-10-25 10:16:00 | Endologix Announces Pricing of Public Offering of Common Stock

2018-10-25 08:03:26 | The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

2018-10-24 16:01:00 | Endologix Announces Public Offering of Common Stock

2018-10-22 16:01:00 | Endologix, Inc. to Announce Third Quarter 2018 Financial Results on November 1, 2018

2018-10-18 08:20:00 | Consolidated Research: 2018 Summary Expectations for Barnes & Noble, Boot Barn, Endologix, Pilgrim's Pride, OraSure Technologies, and Genesco — Fundamental Analysis, Key Performance Indications

2018-10-05 17:46:00 | FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall

2018-10-03 07:54:54 | The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

2018-10-02 16:01:00 | Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range

2018-08-28 08:10:00 | New Research Coverage Highlights MACOM Technology Solutions, Arrowhead Pharmaceuticals, PTC Therapeutics, Boot Barn, Darling Ingredients, and Endologix — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-08-24 22:43:48 | Edited Transcript of ELGX earnings conference call or presentation 9-Aug-18 8:30pm GMT

2018-08-23 16:01:00 | Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-08-23 08:00:00 | Endologix to Host Investor Meeting on October 2, 2018

2018-08-15 08:00:00 | Endologix Appoints Jeffrey S. Brown as Chief Operations Officer

2018-08-10 18:03:00 | Here's Why Endologix Plummeted 37% Today

2018-08-09 17:15:09 | Endologix ELGX Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 16:09:19 | Endologix: 2Q Earnings Snapshot

2018-08-09 16:01:00 | Endologix Reports Second Quarter 2018 Financial Results

2018-08-09 14:30:00 | Endologix, Inc. to Host Earnings Call

2018-08-01 05:06:09 | 3 Dental Stocks to Top Earnings Estimates This Season

2018-07-31 07:31:00 | Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks